Table 2 The relative content of the 15 distinctive metabolites in the validation set. Median(IQR)/mean ± SD. *comparison between control tissues and WHO grades I–II gliomas; #comparison between the control tissues and WHO grades III–IV gliomas, the p of * and # < 0.05. p value in right column means the statistical differences among 3 groups (control, WHO grades I and II and WHO grades III and IV group).

From: Glycerophosphatidylcholine PC(36:1) absence and 3′-phosphoadenylate (pAp) accumulation are hallmarks of the human glioma metabolome

matabolite

Control

WHO grades I and II

WHO grades III and IV

P value

pAp

0.001 (0.000, 0.010)

0.610 (0.503, 0.798)*

0.650 (0.533, 0.743)#

<0.001

Appr > p

0.094 ± 0.019

0.771 ± 0.144*

0.680 ± 0.207#

<0.001

2-Hexaprenyl-6-methoxyphenol

0.048 ± 0.021

0.350 ± 0.096*

0.363 ± 0.126#

<0.001

DG(33:3)

0.110 (0.000, 0.521)

8.121 (5.023, 19.581)*

6.546 (4.714, 8.981)#

<0.001

CE(15:0)

0.218 ± 0.069

1.019 ± 1.127*

0.615 ± 0.209#

0.031

PC(36:1)

110.489 ± 14.283

0.000 ± 0.000*

0.000 ± 0.000#

<0.001

PC(36:3)

0.220 (0.000, 0.341)

6.008 (4.426, 6.610)*

3.019 (2.570, 3.543)#

<0.001

PC(38:6)

2.855 (2.457, 3.748)

3.526 (2.755, 4.448)*

16.551 (15.235, 17.338)#

<0.001

PC(38:4)

0.000 ± 0.000

7.712 ± 2.488*

3.998 ± 2.761#

<0.001

LysoPC(18:0)

0.000 (0.000, 0.003)

0.316 (0.289, 0.426)*

0.396 (0.356, 0.454)#

<0.001

LysoPE(18:3)

0.000 (0.000, 0.002)

0.253 (0.218,0. 374)*

0.203 (0.117, 0.285)#

0.001

LysoPE(20:3)

0.000 (0.000, 0.004)

0.660 (0.556, 0.828)*

0.712 (0.533, 0.881)#

<0.001

LysoPE(18:0)

0.017 ± 0.020

0.741 ± 0.072*

0.716 ± 0.114#

<0.001

Ceramide(d18:1/16:0)

0.019 (0.000, 0.031)

0.785 (0.500, 0.847)*

0.798 (0.639, 0.857)#

<0.001

SM(d18:0/12:0)/C12

0.025 (0.000, 0.102)

8.191 (3.103, 10.808)

6.303 (3.166, 6.832)#

0.009

Back to article page